Related Experiment Video
Updated: Sep 23, 2025

Listeria monocytogenes Infection of the Brain
Published on: October 2, 2018
Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?
Fanfan Xing1, Simon K F Lo1, Susanna K P Lau2
1Department of Clinical Microbiology and Infection Control, The University of Hong Kong - Shenzhen Hospital, Shenzhen, China.
Abstract:
Targeted therapies are widely used for treatment of autoimmune diseases as well as solid organ and hematological malignancies. Various opportunistic infections have been described in patients on targeted therapies. Although case reports or a few case series of listeriosis have been reported to be associated with targeted therapy, most of the cases were related to anti-tumor necrosis factor-α monoclonal antibody. In this study, we describe the epidemiological and clinical profiles of listeriosis in a tertiary hospital in Shenzhen, a Southern Chinese metropolitan city in China. During the 9-year-and-6-month study period, a total of five cases of listeriosis were recorded and all of them had Listeria monocytogenes bacteremia. All five patients had predisposing factors, including corticosteroid (n = 3), targeted therapy (n = 2), pregnancy (n = 2) and anti-interferon gamma autoantibody (n = 1). The two patients who had targeted therapy during their course of cancer treatment received inhibitors of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) pathway. The first one was a 52-year-old woman with metastatic adenocarcinoma of the lung. She was given gefitinib (EGFR tyrosine kinase inhibitor), osimertinib (third-generation EGFR tyrosine kinase inhibitor) and afatinib (tyrosine kinase inhibitor that can bind to EGFR, HER2 and HER4). The second one was a 40-year-old woman with carcinoma of the breast with brain metastasis. She was given trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (dual tyrosine kinase inhibitor of the EGFR/HER2 pathway). These two patients represent the second and third reports of listeria infections associated with EGFR/HER2 pathway inhibitors in the literature. Targeted therapy is an important predisposing factor for listeriosis. Listeria infection is an important differential diagnosis in patients on targeted therapy who present with sepsis and/or central nervous system infection, and the use of antibiotic regimens that cover listeria is crucial for empirical treatment. Avoidance of high-risk food items in these patients is important for the prevention of listeriosis.
Insights
Targeted therapies, particularly those inhibiting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) pathways, are linked to an increased risk of Listeria monocytogenes infections. Early diagnosis and appropriate antibiotic treatment are crucial for patients on these therapies.
Area of Science:
- Infectious Diseases
- Oncology
- Immunology
Background:
- Targeted therapies are increasingly used for autoimmune diseases and malignancies.
- Opportunistic infections, including listeriosis, are known complications in patients receiving targeted therapies.
- Previous reports of listeriosis associated with targeted therapy primarily involved anti-tumor necrosis factor-α monoclonal antibodies.
Purpose of the Study:
- To describe the epidemiological and clinical characteristics of listeriosis in patients at a tertiary hospital in Shenzhen, China.
- To investigate the association between targeted therapy and listeriosis, specifically focusing on inhibitors of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) pathway.
Main Methods:
- Retrospective review of listeriosis cases over a 9-year and 6-month period.
- Analysis of patient data including predisposing factors, clinical presentation, and treatment regimens.
- Detailed examination of two cases involving targeted therapy with EGFR/HER2 pathway inhibitors.
Main Results:
- Five cases of Listeria monocytogenes bacteremia were identified.
- Predisposing factors included corticosteroid use (3 patients), targeted therapy (2 patients), pregnancy (2 patients), and anti-interferon gamma autoantibody (1 patient).
- The two patients on targeted therapy received EGFR/HER2 pathway inhibitors (gefitinib, osimertinib, afatinib, trastuzumab, lapatinib), representing rare instances of listeria infection linked to these agents.
Conclusions:
- Targeted therapy, especially EGFR/HER2 pathway inhibitors, is a significant predisposing factor for listeriosis.
- Listeriosis should be considered in patients on targeted therapy presenting with sepsis or central nervous system infections.
- Empirical antibiotic treatment covering Listeria and avoidance of high-risk foods are crucial for prevention and management.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Acute Pyelonephritis II: Diagnostic Studies and Management
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Targeted Cancer Therapies
There are several types of targeted therapies against...

